Drug giant Pfizer and its partner BioNTech have begun an advanced trial of one of their experimental coronavirus vaccines in the US. The combined Phase 2/3 trial, which looks for safety, efficacy and optimal dosing, will include up to 30,000 participants.
The first four participants were dosed Monday at the University of Rochester Medical Center, a spokesman there said. The combined Phase 2/3 trial, which looks for safety, efficacy and optimal dosing of a vaccine or drug, will include up to 30,000 participants.It was the second advanced trial of a coronavirus vaccine to get under way in the United States Monday. Earlier Monday, Moderna started a Phase 3 trial in the United States of its experimental vaccine.
If the vaccine works, Pfizer and BioNTech say they're on track to seek regulatory review as early as October, and if it wins emergency authorization from the US Food and Drug Administration, they could supply up to 100 million doses by the end of 2020, and about 1.3 billion by the end of 2021.Last week the US Department of Health and Human Services and Department of Defense announced a $1.95 billion agreement with Pfizer to produce 100 million doses of a Covid-19 vaccine.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday
Weiterlesen »
Pfizer, BioNTech could submit vaccine for approval by Oct – latest updatesPfizer, BioNTech could submit vaccine for approval by October. Other Covid19 updates: 🌍 Virus-linked hunger tied to 10,000 child deaths a month 🇧🇴 Bolivian prisoners riot over virus exposure 🇰🇪 Kenya extends lockdown by 30 days More here:
Weiterlesen »
Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidateGerman biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
Weiterlesen »
Pfizer rethinking U.S. expansion if drug pricing orders implementedPfizer Inc Chief Executive Albert Bourla said the drugmaker could rethink plans to expand in the United States if the country implements an executive order signed by President Donald Trump last week that would tie the prices Medicare patients pay for drugs to those paid by other countries.
Weiterlesen »
Pfizer CEO says Trump's executive orders overhauling U.S. drug pricing will upend the industryTrump signed four executive orders designed to bring U.S. drug prices at least on par with their costs overseas.
Weiterlesen »
Pfizer profit falls 32% as global trial of COVID-19 vaccine candidate beginsPfizer Inc reported a 32% fall in second-quarter profit on Tuesday due to a dip in demand for some of its drugs from the COVID-19 pandemic and from rising competition, as the company and partner began a global study into a vaccine candidate to fight the health crisis.
Weiterlesen »